Longevity swaps 'a natural hedge' for pharmaceutical and care home industries, says Swiss Re


As longevity risk attracts increasing attention among pension funds, market participants are questioning reinsurers’ capacity to cope with the growing demand, and are looking for alternative solutions. Pharmaceutical and care homes could provide the answer, according Swiss Re.

Daniel Ryan, head of life and health research at Swiss Re, suggests the nature of both industries means they could benefit from increasing longevity, making them ideal counterparties for longevity swap deals. “There are

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: